Brief: Mirum Pharmaceuticals Announces Positive Results From Cohort 2 Of The Pivotal Progress Study Of Atebrioz™ (Zilurgisertib) In Pediatric Patients Aged 6 To <12 Years With Fibrodysplasia Ossificans Progressiva
26/10/2026 12:01
BRIEF-Mirum Pharmaceuticals Announces Positive Results From Cohort 2 Of The Pivotal Progress Study Of Atebrioz™ (Zilurgisertib) In Pediatric Patients Aged 6 To <12 Years With Fibrodysplasia Ossificans Progressiva Oct 26 (Reuters) - Mirum Pharmaceuticals, Inc. MIRM.O:
MIRUM PHARMACEUTICALS ANNOUNCES POSITIVE RESULTS FROM COHORT 2 OF THE PIVOTAL PROGRESS STUDY OF ATEBRIOZ™ (ZILURGISERTIB) IN PEDIATRIC PATIENTS AGED 6 TO <12 YEARS WITH FIBRODYSPLASIA OSSIFICANS PROGRESSIVA
MIRUM PHARMACEUTICALS - ATEBRIOZ REDUCED HO LESION VOLUME AND IMPROVED JOINT MOBILITY AT WEEK 24; NO NEW HO LESIONS
MIRUM PHARMACEUTICALS - ATEBRIOZ WELL TOLERATED; NO NEW SAFETY SIGNALS IDENTIFIED
MIRUM PHARMACEUTICALS - PLANS SNDA SUBMISSION IN H1 2027 TO EXPAND ATEBRIOZ INDICATION TO AGES 6 TO <12
Source text: ID:nBw1xGLMza
Further company coverage: MIRM.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Mirum Pharmaceuticals
See all newsMirum Pharmaceuticals Q3 net product sales surge, outlook raised
Brief: Mirum Pharmaceuticals Announces Positive Results From Cohort 2 Of The Pivotal Progress Study Of Atebrioz™ (Zilurgisertib) In Pediatric Patients Aged 6 To <12 Years With Fibrodysplasia Ossificans Progressiva
Mirum climbs on positive late-stage trial results for liver disease drug
US STOCKS ON THE MOVE-Mirum Pharmaceuticals, Meta, Boeing
U.S. STOCKS ON THE MOVE-Royal Caribbean Cruises, SpaceX